過敏治療藥產品線及研究開發動向：2009年

過敏治療藥產品線及研究開發動向：2009年 是由出版商Fuji-Keizai U.S.A., Inc.在2009年06月所出版的。 這份英文市場調查報告書包含126 PAGES 價格從美金995起跳。

目錄

Abstract

This report describes current global research initiatives in the field of allergies. It focuses on the most common allergies, which affect more than 300 million persons worldwide: seasonal and perennial allergic rhinitis and food allergies.

Sales estimates from 2008 to 2013 are provided for the leading prescription allergy drugs and vaccines, as well as over-the-counter (OTC) allergy medicines in the U.S., European Union, Japan and rest of world area (defined as South America and the Caribbean, Middle East, Africa, and Asia except Japan). Forecasts include an analysis of the market forces affecting sales in each region, as well as a discussion of patent expirations of leading medications and the effects of generic competition on existing allergy drug sales.

Allergy medications and vaccines under development are discussed, with a comprehensive analysis of technology, stage of development and commercialization potential. This includes new molecular entities and indication expansions of medicines currently approved for other uses. For leading allergy drug candidates, sales estimates from 2009 to 2013 are provided.

Profiles of the 12 leading allergy drug developers offer details of these companies' capabilities, particularly focusing on R&D strength, pipeline products, strategic alliances and partnerships, and the effects of any recent merger or acquisition activity. A directory of more than five dozen leading players worldwide allows readers to access companies' own web sites for further review.

Information for this report was gathered from a wide variety of published sources; interviews with company representatives were then conducted to assess trends, and form the basis of the forecasting and competitive analysis.

This report is designed for business development and other senior executives, marketers, R&D managers, investors, VCs, consultants, entrepreneurs and others who require an in-depth understanding of the current status of the allergy therapeutics market and potential new products. More than 50 detailed tables or figures provide key data about items such as strategic alliances, M&As, market size, segments and the like.

Table of Contents

Executive Summary

1. Overview of the Global Allergy Medications Market

• 1.1 Allergies as a Medical Condition
  • 1.1.1 Types of Allergies
  • 1.1.2 Signs and Symptoms
  • 1.1.3 Physiological Response
    • Table 1-1. Gell & Coombs Classification of Allergic Reactions
  • 1.1.4 Prevalence
    • Table 1-2. Global Prevalence of Allergies
• 1.2 Medical Treatment of Allergies
  • 1.2.1 Prescription Medications: Current Usage & Unmet Needs
    • Table 1-3. Leading Prescription Allergy Medications
    • 1.2.1.1 U.S.
      • Table 1-4. U.S. DTC Advertising for Leading Rx and OTC Allergy Medications 2008
    • 1.2.1.2 Europe
    • 1.2.1.3 Japan
    • 1.2.1.4 ROW
  • 1.2.2 Non-Prescription Products: Current Usage & Unmet Needs
    • Table 1-5. Leading OTC Allergy Medications
  • 1.2.2.1 U.S.
  • 1.2.2.2 Europe
  • 1.2.2.3 Japan
  • 1.2.2.4 ROW

2. Global Allergy Medications Market Forecast 2008 - 2013

• 2.1 Rx Allergy Medications Market
  • 2.1.1 Rx Allergy Drug Market Forecast by Product
    • 2.1.1.1 Growth Drivers
      • Table 2-1. Rx Allergy Drug Market Forecast 2008 - 2013 by Product in $Million
    • 2.1.1.2 Market Restraints
      • Table 2-2. U.S. Patent Expirations of Leading Prescription Allergy Drugs
  • 2.1.2 Rx Allergy Drug Market Forecast by Region
    • Table 2-3. Rx Allergy Drug Market Forecast, 2008 - 2013 by Region in $ Million
  • 2.1.3 Rx Allergy Drug Market Forecast by Product Class
    • Table 2-4. Rx Allergy Drug Market Forecast, 2008 - 2013 by Product Class in $ Million
    • Table 2-5. Rx Allergy Drug Market Product Segments Share, 2008 vs. 2013
  • Figure 2-1. Rx Allergy Drug Market Product Segments Share, 2008
  • Figure 2-2. Rx Allergy Drug Market Product Segments Share, 2013
• 2.2 OTC Allergy Drug Market
  • 2.2.1 OTC Allergy Drug Market Forecast by Product
    • Table 2-6. OTC Allergy Drug Market Forecast, 2008 - 2013 by Product in $Million
  • 2.2.2 Growth Drivers
  • 2.2.3 Market Restraints
  • 2.2.4 OTC Allergy Drug Market Forecast by Region
    • Table 2-7. OTC Allergy Drug Market Forecast, 2008 - 2013 by Region in $ Million
  • 2.2.5 OTC Allergy Drug Market Forecast by Product Class
    • Table 2-8. OTC Allergy Drug Market Forecast, 2008 - 2013 by Product Class in $ Million
• 2.3 Rx & OTC Allergy Drug Market
  • 2.3.1 Rx & OTC Allergy Drug Market Forecast by Leading Manufacturers
    • Table 2-9. RX & OTC Allergy Drug* Sales of Leading Manufacturers, 2008 - 2013 in $Million
  • 2.3.2 Rx & OTC Allergy Drug Market Share of Leading Drug Manufacturers
    • Table 2-10. Rx & OTC Market Shares of Leading Allergy Drug Manufacturers, 2008 vs. 2013
  • Figure 2-3. Rx & OTC Market Shares of Top Allergy Drug Manufacturers, 2008
  • Figure 2-4. Rx & OTC Market Shares of Top Allergy Drug Manufacturers, 2013

3. Allergy Drug Development: New Molecular Entities

• Table 3-1. Key Characteristics of NMEs, Generics and Indication Expansions
• 3.1 All Allergy Drug Developers Position
  • 3.1.1 Challenges in Allergy Drug Development
    • Table 3-2. All Allergy Drug Developers Product Position Overview
• 3.2 Key Products Under Development
  • Figure 3-1. Allergy Compounds Tested by Phase of Development
  • 3.2.1 Antihistamines
    • 3.2.1.1 Physiology and Mechanism of Action
    • 3.2.1.2 Leading Antihistamine Allergy Drug Candidates
      • Table 3-3. Antihistamine Developers Product Position
  • 3.2.2 Corticosteroids
    • 3.2.2.1 Physiology and Mechanism of Action
    • 3.2.2.2 Leading Corticosteroid Allergy Drug Candidates
      • Table 3-4. Corticosteroid Developers Product Position
  • 3.2.3 Mast Cell Inhibitors
    • 3.2.3.1 Physiology and Mechanism of Action
      • Figure 3-2. The Role of Mast Cells in Allergy Response
    • 3.2.3.2 Leading Mast Cell Inhibitor Allergy Drug Candidates
      • Table 3-5. Mast Cell Inhibitors Developers Product Position
  • 3.2.4 Allergy Immunotherapy
    • 3.2.4.1 Physiology and Mechanism of Action
    • 3.2.4.2 Leading Immunotherapy Allergy Drug Candidates
      • Table 3-6. Immunotherapy Developers Product Position
  • 3.2.5 Vaccines
    • 3.2.5.1 Physiology and Mechanism of Action
      • Figure 3-3. Production of TH2 Cytokines
    • 3.2.5.2 Leading Allergy Vaccine Candidates
      • Table 3-7. Vaccine Developers Product Position
  • 3.2.6 Other Types of Allergy Drugs
    • 3.2.6.1 Physiology and Mechanism of Action
    • 3.2.6.2 Other Leading Allergy Candidates
      • Table 3-8. Other Allergy Drug Developers Product Position
• 3.3 Global Market Forecast for New Allergy Drugs, 2008 - 2013
  • 3.3.1 New Allergy Drug Market Forecast: Total and Segment Market
    • Table 3-9. Sales of New Allergy Drugs by Segment, 2008 - 2013
    • Figure 3-4. Market Shares of New Allergy Drugs by Segment, 2013
  • 3.3.2 Growth Drivers
    • 3.3.2.1 The Importance of Patents
  • 3.3.3 Market Restraints

4. Allergy Drug Development: Indication Expansion

• 4.1 Indication Expansion for New Usage
  • Table 4-1. Selected Recent Allergy Drug Indication Expansions, U.S.
  • 4.1.1 The Economic Benefits of Indication Expansion
    • Table 4-2. U.S. R&D Expenditure for New Medicines by the Pharma-Industry
  • 4.1.2 Challenges in Allergy Drug Indication Expansion
    • Figure 4-1. Cost and Time Savings of Indication Expansions
• 4.2 Key Products Under Development
  • 4.2.1 Database of Allergy Indication Expansion Initiatives by Company
    • Table 4-3. Selected Allergy Drug Indication Expansion Trials
  • 4.2.2 Leading Areas of R&D Activity
    • 4.2.2.1 Clarinex
    • 4.2.2.2 Nasonex
    • 4.2.2.3 Patanase
    • 4.2.2.4 Singulair
    • 4.2.2.5 Veramyst
    • 4.2.2.6 Xolair
    • 4.2.2.7 Xyzal
• 4.3 Global Market Forecast for Allergy Drug Indication Expansions
  • Table 4-4. Sales of Allergy Drug Indication Expansions, 2008 - 2013 in $ Million
  • Table 4-5. Product Market Share of Allergy Drug Indication Expansions, 2009 vs. 2013
  • Figure 4-2. Product Market Share of Allergy Drug Indication Expansions, 2009
  • Figure 4-3. Product Market Share of Allergy Drug Indication Expansions, 2013
  • 4.3.1 Growth Drivers
  • 4.3.2 Market Restraints

5. Allergy Drug Development: Basic Research

• 5.1 Basic Research Group & Activity
  • Table 5-1. Leading Organizations & Details for Basic Allergy Research
  • 5.1.1 Challenges in Basic Allergy Research
    • Figure 5-1. National Institutes of Health Research Budget by Disease Area, Fiscal 2008
• 5.2 Key Areas of Investigation
  • Table 5-2. Recent Basic Research in the Field of Allergies
• 5.3 Unanswered Questions

6. Strategic Alliances for Allergy Drug Development

• 6.1 Types of Strategic Alliances
  • Figure 6-1. Comparison of Selected Deal Types
• 6.2 Current Strategic Alliances for Allergy Drug Development
  • Table 6-1. Ongoing Strategic Alliances for Allergy Drug Development

7. Activities of the Leading Allergy Drug Developers Common Research Item:

• 1) Table: Product Profile:
• 2) R&D Strength and Capabilities
• 3) Marketed Allergy Drugs
• 4) Allergy Drug Pipeline
• 5) Table: Profile

• 7.1 Alcon Research
• 7.2 Allergy Therapeutics
• 7.3 AstraZeneca
• 7.4 GlaxoSmithKline
• 7.5 Johnson & Johnson
• 7.6 Meda AB
• 7.7 Merck
• 7.8 Novartis
• 7.9 Sanofi-Aventis
• 7.10 Schering-Plough
• 7.11 Sepracor
• 7.12 UCB Pharma

8. Total Allergy Drug Market: Forecasts & Directions

• Table 8-1. Total Allergy Drug Sales by Segment, 2008 - 2013 in $Million
• Figure 8-1. Total Allergy Drug Sales Growth by Segment, 2008 - 2013
• Figure 8-2. Allergy Drug Market Share by Segment, 2008
• Figure 8-3. Allergy Drug Market Share by Segment, 2013

9. Other Top Companies with Allergy Projects

• Table 9-1. Other Top Companies with Late Stage Allergy Projects
• Table 9-2. Other Top Companies with Early Stage Allergy Projects

10. Database of Allergy Drug Developers

相關商品

藥物開發相關市場調查報告書

乳癌，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Breast Cancer, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

大腸癌，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Colorectal Cancer, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

白血病，肺癌，血管新生:藥物開發策略分析
Triple Analysis: Leukemia, Lung Cancer and Angiogenesis
價格 : US $ 5175
出版日期 : 2012年01月

Fuji-Keizai U.S.A., Inc.發行的製藥相關市場調查報告書

高齡化所伴隨的疾病用醫藥品市場動向與新藥開發相關調査

(JV) Drugs for the Diseases of Aging

價格 : US $ 1495

出版日期 : 2011年11月

隨著年齡而產生的疾病的藥劑：美國50歲以上人口主要使用的處方藥市場與動向

Drugs for the Diseases of Aging: US Markets and Trends for Prescription Medicines Used Predominantly by Persons Age 50 and older

價格 : US $ 1495

出版日期 : 2011年10月

全球個別化醫療市場

Worldwide Personalized Medicine Market

價格 : US $ 1495

出版日期 : 2010年08月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!